        | ||||
    Medication Discontinuation Alert November 5, 2007
The following was excerpted from Pfizer’s "Dear Customer" Letter dated October 18, 2007: "On Thursday Oct 18th, Pfizer announced that it will be returning the worldwide rights for Exubera (insulin human [rDNA origin]) Inhalation Powder back to Nektar, the company from which we licensed the inhaled insulin technology. What this means is that Pfizer will support current Exubera patients for the next 3 months as they transition to other glucose-lowering therapies, but after that we will no longer sell Exubera. Customers who have Exubera inventory can continue to hold their stock past 90 days to cover any residual Rx fills or can return their inventory using normal procedures for Pfizer products. Although we have made a decision to no longer produce Exubera we would like to emphasize that this is a decision to stop marketing Exubera; it is not a product recall, nor the result of any specific safety signal that would put patients at risk. While Exubera remains a safe and effective medicine, it simply has not met the needs of customers and prescribing physicians in managing patients with diabetes. We are making available to patients (through the Exubera website and Exubera Call Center) and Healthcare Practitioners who have prescribed Exubera (through regular mail, the PfizerPro website and the Field Force), information on what to do in terms of transitioning from Exubera use to alternative glucose lowering medications. A copy of the letters being provided to physicians and patients can be found on www.PfizerPro.com. If you require further information, please contact:
|
||||
     |